Arbutus Biopharma
ABUS
49 hedge funds and large institutions have $65.5M invested in Arbutus Biopharma in 2014 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 15 increasing their positions, 10 reducing their positions, and 18 closing their positions.
137% more call options, than puts
Call options by funds: $8.69M | Put options by funds: $3.66M
50% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 10
17% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 18
2% more funds holding
Funds holding: 48 → 49 (+1)
35% less capital invested
Capital invested by funds: $100M → $65.5M (-$34.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$10.2M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.02M |
| 3 |
SIA
Sit Investment Associates
Minneapolis,
Minnesota
|
+$1.64M |
| 4 |
Citigroup
New York
|
+$1.51M |
| 5 |
B
Bailard
Foster City,
California
|
+$1.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$7.93M |
| 2 |
Morgan Stanley
New York
|
-$7.14M |
| 3 |
BG
BlackRock Group
London,
United Kingdom
|
-$2.41M |
| 4 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$2.11M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.08M |
ABUS Hedge Fund Activity: Q4 2014 in Review
49 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q4 2014, worth a combined $65.5M — down 35% from $100M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ABUS positions and 18 closed out — a net gain of 3 holders — while 15 added to existing stakes and 10 trimmed.
The largest buyer was Franklin Resources, adding an estimated $10.2M. The largest seller was BlackRock Advisors, exiting entirely with an estimated $7.93M sold.
- 49 institutional investors held Arbutus Biopharma (ABUS) as of Q4 2014, up from 48 in Q3 2014.
- Funds reported $65.5M of Arbutus Biopharma stock for Q4 2014, down 35% quarter-over-quarter.
- 21 funds opened new Arbutus Biopharma positions in Q4 2014 and 18 closed out, a net change of +3 holders.
- The largest Arbutus Biopharma buyer in Q4 2014 was Franklin Resources, an estimated $10.2M added.
- The largest Arbutus Biopharma seller in Q4 2014 was BlackRock Advisors, an estimated $7.93M sold.
Based on aggregated 13F filings for Q4 2014.